Mineralys Therapeutics, Inc. MLYS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Returns | ||||
| Return on equity | -36.9%+45.3pp | -82.2%— | —— | |
| Return on assets | -35.6%+42.1pp | -77.7%-38.4pp | -39.3%— | |
| Liquidity | ||||
| Current ratio | 43.8×+29.7× | 14×-9.7× | 23.8×+9.8× | |
| Quick ratio | 43.8×+29.7× | 14×-9.7× | 23.8×+9.8× | |
| Cash ratio | 0.1×0.0× | 0×0.0× | 0.1×-0.3× | |
| Leverage | ||||
| Interest coverage | -10.7×+2.5× | -13.2×-6.6× | -6.6×+12.1× | |
| Per Share | ||||
| Book value per share | $9.56+143% | $3.94-40.9% | $6.66+166% | |
| Valuation | ||||
| Market capitalization | $2.87B+369% | $612.65M+77.7% | $344.8M— | |
| Price / book | 4.4×+1.2× | 3.2×+1.8× | 1.4×— | |
| Free cash flow yield | -5%+22.2pp | -27.2%-3.6pp | -23.5%— | |
| Earnings yield | -5.4%+23.6pp | -29%-8.2pp | -20.9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mineralys Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Mineralys Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.